This announcement is a separate document:
復宏漢霖：自願公告 - HLX53（抗TIGIT的Fc融合蛋白）聯合漢斯狀（斯魯利單抗注射液） 及漢貝泰（貝伐珠單抗注射液）一線治療局部晚期或轉移性肝細胞癌的 臨床試驗申請獲國家藥品監督管理局批准
HENLIUS: VOLUNTARY ANNOUNCEMENT - APPLICATION FOR THE CLINICAL TRIAL OF HLX53 (ANTI-TIGIT FC FUSION PROTEIN) IN COMBINATION WITH HANSIZHUANG (SERPLULIMAB INJECTION) AND HANBEITAI (BEVACIZUMAB INJECTION) FOR THE FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.